Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Rating of “Reduce” by Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been assigned an average recommendation of “Reduce” from the nine analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $28.00.

Several brokerages have commented on FMS. Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, March 13th. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research note on Tuesday, February 24th. Truist Financial set a $28.00 target price on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Finally, Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.3%

FMS stock opened at $22.48 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.92 and a current ratio of 1.26. The company has a market capitalization of $12.55 billion, a price-to-earnings ratio of 11.77, a PEG ratio of 2.12 and a beta of 0.89. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The stock has a fifty day moving average of $23.10 and a 200-day moving average of $23.99.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Saturday, February 14th. The company reported $1.69 earnings per share (EPS) for the quarter. The company had revenue of $5.95 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the period. Arax Advisory Partners boosted its stake in Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $58,000. Finally, Group One Trading LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at about $74,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.